Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2580 of 9102 results

  1. Orforglipron for managing overweight and obesity [ID6516]

    In development Reference number: GID-TA11650 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  2. Luspatercept for treating haemoglobin H disease [ID6714]

    Awaiting development Reference number: GID-TA11940 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Teprotumumab for treating thyroid eye disease [ID6432]

    Deferred Reference number: GID-TA11531

    Technology appraisal guidance
    Deferred

  4. Tarlatamab for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]

    In development Reference number: GID-TA11812 Expected publication date:  13 January 2027

    Technology appraisal guidance
    In development

  5. Tucatinib with pertuzumab and trastuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

    Awaiting development Reference number: GID-TA11487 Expected publication date:  27 May 2027

    Technology appraisal guidance
    Awaiting development

  6. Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]

    In development Reference number: GID-TA11130 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Point-of-care lipid tests for cardiovascular disease prevention in primary and community care

    Awaiting development Reference number: GID-HTG10528 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  8. Artificial intelligence (AI)-derived software to help clinical decision making in stroke

    Awaiting development Reference number: GID-HTG10529 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  9. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication

    Awaiting development Reference number: GID-HTG10530 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  10. Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]

    Awaiting development Reference number: GID-TA11626 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Epilepsies in children, young people and adults (extraordinary review)

    In development Reference number: GID-NG10378 Expected publication date: TBC

    NICE guideline
    In development

  12. Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care

    Awaiting development Reference number: GID-HTG10531 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  13. Belzutifan for treating advanced pheochromocytoma or paraganglioma [ID6719]

    Awaiting development Reference number: GID-TA11928 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]

    Awaiting development Reference number: GID-TA11917 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]

    Technology appraisal Reference number: TA582 Published:  24 May 2019

    Technology appraisal guidance
    In development